| "A 12-week, multicenter, randomized, double-blind, placebo-controlledstudy to assess the efficacy and safety of QAW039 when added tostandard-of-care asthma therapy in patients with uncontrolled asthma" |
Ongoing |
QAW039/Fevipiprant |
3 |
CQAW039A2316 |
King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Jeddah) |
| "A 2-treatment period, randomized, placebo-controlled,multicenter parallel-group study to assess the safety ofQAW039 when added to existing asthma therapy in GINAsteps 3, 4 and 5 patients with uncontrolled asthma" |
Ongoing |
QAW039/Fevipiprant |
3 |
CQAW039A2315 |
King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Jeddah) |
| "A PHASE III, MULTICENTER,RANDOMISED, DOUBLEBLIND,PLACEBOCONTROLLEDSTUDY OF ATEZOLIZUMAB (ANTI−PDL1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER" |
Ongoing |
ATEZOLIZUMAB / PACLITAXEL |
3 |
MO39196 |
International Medical Center (Jeddah), King Fahad Specialist Hospital (Dammam), King Fahad Medical City (Riyadh) |
| Randomized, four-way, four-period, single oral dose, open-label, crossover, bioequivalence study to compare Tacrolimus Immediate-release capsules (5 mg tacrolimus) versus Prograf® Immediate-release capsules (5 mg tacrolimus), in healthy subjects under fasting conditions. |
Ongoing |
Tacrolimus/ Prograf |
BE |
19-2017 |
Saudi Ajal |
| "A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack[THALES - Acute STroke or Transient IscHaemic Attack Treated with TicAgreLor and ASA for PrEvention of Stroke and Death]" |
Ongoing |
Ticagrelor |
3 |
D5134C00003 |
King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah) |
| A Randomized, Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Endocrine Therapy Alone in Patients with High Risk Node Positive Early Stage Hormone Receptor Positive, Human Epidermal Receptor 2 Negative Breast Cancer |
Ongoing |
abemaciclib |
3 |
I3Y-MC-JPCF |
King Fahad Medical City (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Specialist Hospital (Dammam) |
| A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors |
Ongoing |
ABL001 |
3 |
CABL001A2301 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Follow-up of Phase I/II study of CaspaCIDe T cells (BPX-501) from an HLA-partially matched family donor after negative selection of TCR αβ+T cells in pediatric patients affected by hematological disorders |
Ongoing |
Rimiducid |
2 |
CT17-008-R |
King Abdulaziz Medical City NG (Riyadh) |
| Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Angiotec tablets (20 mg enalapril) Produced by JPM / Jordan versus Renitec® tablets (20 mg enalapril) Produced by Merck Sharp & Dohme / UK, in healthy subjects under fasting condition. |
Ongoing |
Angiotec |
BE |
Jun-17 |
Saudi Ajal |
| An observational disease and clinical outcomes registry of patients with acid lipase (LAL) deficiency |
Ongoing |
Kanuma |
4 |
ALX-LALD-5 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
